PureTech reported $220 million in cash and short-term investments at the parent-company level and expects its operational runway to last through at least the end of 2028, excluding potential monetization proceeds. Portfolio financing advanced significantly: Seaport Therapeutics raised $260 million through its Nasdaq IPO, while Celea Therapeutics secured $180 million and began a global Phase III trial for deupirfenidone in idiopathic pulmonary fibrosis. Gallop Oncology received FDA Fast Track designation for LYT-200 in relapsed or refractory high-risk MDS and plans to begin a 125-patient Phase II trial once external financing—potentially through equity or a pharmaceutical partnership—is secured.
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entities. Chief Executive Officer Robert Lyne said the company entered the first half with $220 million in cash equivalents and short-term investments at the PureTech level and continues to expect its operational runway to extend at least through the end of 2028. The runway assumption excludes any proceeds from potential monetization events involving its founded entities. → These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories Lyne said PureTech is refining its hub-and-spoke model to pursue greater capital efficiency while translating portfolio value more directly to shareholders.
The company develops programs internally, then seeks to scale them through separately financed founded entities while retaining equity interests as well as potential milestones and royalties. Seaport Therapeutics completed a Nasdaq initial public offering in May that raised $260 million in gross proceeds, following private financings completed in 2024. PureTech holds a 31.2% equity interest in Seaport, which Lyne said was valued at approximately $360 million as of Sept. 18, 2026.
PureTech also retains royalty and milestone rights related to Seaport. → Lennar's Earnings Miss May Be Sending a Bigger Warning About U.S. Housing Celea Therapeutics, PureTech's pulmonary-focused spinout, secured $180 million from healthcare investors and began its global Phase III SURPASS-IPF trial of deupirfenidone for idiopathic pulmonary fibrosis. Deupirfenidone is designed to improve on FDA-approved pirfenidone through deuteration, according to the company.
PureTech holds a 35.4% equity stake in Celea and retains royalties, milestone payments and sublicense-income rights. Lyne said $17.5 million of PureTech's overall $30 million contribution to Celea's financing occurred after the June half-year end. The company has also reserved $70 million for potential future investment in Celea, though the amount is not legally committed. → Priced for a Pullback or More Gains?
These 3 Stocks Are Testing the Limits Lyne said Celea's Phase III program shifts substantial development expenses out of PureTech. He said PureTech expects future annual cash burn, including overhead and innovation spending, of roughly $30 million to $40 million, compared with approximately $90 million annually while later-stage programs were being run internally. On the company's remaining economics from Cobenfy, the FDA-approved schizophrenia treatment marketed by Bristol Myers Squibb, PureTech said it has generated more than $1 billion from the collective Karuna Therapeutics and Cobenfy economics.
Extract — continue reading at the source.
